Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Henry MD
David Henry MD Advisory Board
Elizabeth Smyth MD
Elizabeth Smyth MD Advisory Board
Rafael Fonseca MD
Rafael Fonseca MD Editor-in-Chief
See All Experts
story of the week
Published in Oncology

Journal Scan / Research · September 12, 2019

Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma

JAMA Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Paul Hampel MD

JAMA Oncology
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial
JAMA Oncol 2019 Sep 05;[EPub Ahead of Print], GK Abou-Alfa, Q Shi, JJ Knox, A Kaubisch, D Niedzwiecki, J Posey, BR Tan, P Kavan, R Goel, PE Lammers, TS Bekaii-Saab, VC Tam, L Rajdev, RK Kelley, I El Dika, T Zemla, RI Potaracke, J Balletti, AB El-Khoueiry, JH Harding, JM Suga, LH Schwartz, RM Goldberg, MM Bertagnolli, J Meyerhardt, EM O'Reilly, AP Venook

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated